NAUT: תחזית קונצנזוס אנליסטים Nautilus Biotechnology

Nautilus Biotechnology (NAUT) is a pioneer in proteomics, implementing AI solutions to study protein structures. This chart illustrates the asset's price action, with a value of 3.85. The business model relies on the sale of software and nanotechnologies without owning manufacturing plants, leveraging a tight circle of experts. The current development status limits pricing power until the method's effectiveness prior to mass spectrometry is confirmed.

For Nautilus Biotechnology (NAUT), which is developing a proteomic analysis platform, this indicator serves as a gauge of market confidence in the commercialization of its drug discovery system. The metric is calculated as the arithmetic mean of target prices from leading analysts, reflecting the aggregate fundamental value of the business. By analyzing the consensus target price, an investor can assess the volatility of expectations regarding the issuer's technological superiority over its competitors.